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Wnt signalling pathways have been shown to play key roles
in both normal development and tumorigenesis. Progression of
many human cancers is associated with deﬁned mutations in
Wnt pathway components that result in dysregulated β-catenin-
mediated gene transcription. Although Wnt pathway mutations
are rare in epithelial ovarian cancer (with the exception of the
endometrioid histotype), accumulating evidence supports a role
for Wnt signalling in ovarian tumorigenesis in the absence of
genetic mutations. The present review summarizes evidence in
support of activated Wnt signalling in ovarian tumours and
discusses alternative mechanisms for Wnt pathway activation in
the ovarian tumour microenvironment.
Key words: β-catenin, endothelin, integrin, lysophosphatidic
acid, microenvironment, ovarian cancer, T-cell factor/ lipoprotein
receptor-related (Tcf/Lef), Wnt.
INTRODUCTION
Overview of canonical Wnt signalling
Wnt signalling regulates a diversity of processes fundamental to
embryogenesis, including proliferation, differentiation, polarity,
adhesion and motility [1–3]. The highly conserved and
complex Wnt pathway transduces signals from the extracellular
environment through transmembrane receptors and co-receptors
to have an impact on cytoskeletal rearrangements and gene
expression changes and thereby modulate cell behaviour. In
the adult organism, aberrant activation of these same biological
processes can induce neoplasia and promote tumour progression
[4]. There are two distinct pathways for transduction of Wnt
signals: the canonical Wnt/β-catenin pathway (Figure 1) and
the non-canonical β-catenin-independent pathway. The latter can
be subdivided further into Wnt/PCP (planar cell polarity) and
Wnt/Ca
2+ signalling pathways. Many excellent reviews have
been recently published that detail both the canonical and non–
canonical Wnt pathways, thus the present review will provide
only a brief summary of the canonical pathway as it relates to
EOC (epithelial ovarian carcinoma).
Canonical Wnt signalling is commonly activated by secreted
proteins in the Wnt family, which currently consists of 19
members [1–3,5]. Wnts bind to transmembrane Fzd (Frizzled)
GPCRs (G-protein-coupled receptors). Interaction of ligated
Fzd with co-receptors designated LRP (lipoprotein receptor-
related protein)-5 or LRP-6, members of the low-density
LRP family, initiates Wnt signalling. In the absence of Wnt
signalling, β-catenin functions as a structural component of
E-cadherin (epithelial cadherin) junctions and is complexed
with the cytoplasmic tail of E-cadherin. In normal epithelial
cells, the majority of β-catenin is associated with E-cadherin
at cell–cell junctions, and the levels are maintained at low
concentrations in the cytoplasm by phosphorylation-dependent
degradation of β-catenin. Cytoplasmic β-catenin is targeted to
a complex comprised of Axin, APC (adenomatous polyposis
coli) and GSK3β (glycogen synthase kinase 3β), resulting in
phosphorylation of β-catenin that targets it for degradation
through the ubiquitin–proteasome pathway (Figure 1A).
Activation of Wnt signalling leads to phosphorylation of LRP-
5/6, recruitment of Axin and Dvl (Dishevelled 1) to the plasma
membrane,andfunctionaldisruptionoftheβ-catenindegradation
complex. This in turn enables accumulation of cytoplasmic β-
catenin, which can then translocate to the nucleus, bind proteins
in the Tcf (T-cell factor)/Lef (lymphoid enhancer factor) family,
and activate transcription of Wnt target genes. Wnt signalling
can be inhibited by sequestration of Wnt ligands via interaction
with SFRP (secreted Fzd-related protein) or WIF (Wnt-inhibitory
factor)-1 as well as by blocking co-receptor binding between
Kremen and LRP-5/6 via Dkk (Dickkopf).
Accumulation of non-junctional β-catenin, and in particular
nuclear translocation, is used as a surrogate marker for activation
of the Wnt/β-catenin pathway. This is observed in a number of
human cancers, as summarized below, and often results from
mutations in Wnt pathway components. With the exception of
the endometrioid histotype, Wnt pathway mutations are rare in
ovarian cancer [6,7]. However, accumulating evidence suggests a
role for Wnt signalling in ovarian tumorigenesis in the absence
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Figure 1 Canonical Wnt signalling and nuclear β-catenin in ovarian tissue
(A)IntheabsenceofWntpathwayactivation,β-cateniniseitherassociatedwiththecytoplasmic
tailofE-cadherinoristargetedtoanAxin/APC/GSK3β complexwhereuponitisphorphorylated
and targeted for degradation (left-hand panel). Activation of Wnt signalling, for example by
binding of Wnt to the Fzd receptor, results in association of the co-receptors LRP-5/6 with Fzd
andrecruitmentofDvltoFzdattheplasmamembrane.BindingofAxintothiscomplexdisrupts
the β-catenin degradation complex, enabling accumulation of β-Catenin. β-Catenin can then
translocate to the nucleus, bind to Tcf/Lef transcription factors and transcriptional co-activators
(not shown) to activate transcription of Wnt target genes. Wnt signalling can be blocked by Dkk
that binds Kremen and inhibits the interaction between Fzd and LRP-5/6, or by sequestration
of Wnt ligands via WIF or SFRP (right-hand panel). (B) Example of a serous ovarian tumour
exhibiting nuclear β-catenin staining. Magniﬁcation ×200.
of genetic mutations, suggesting alternative mechanisms for Wnt
pathway activation in EOC (Figure 1B) [8–10].
Ovarian tumours inhabit a unique metastatic niche
EOC is a leading cause of death from gynaecologial malignancy.
Worldwide, each year approximately 204000 women are
diagnosed with EOC, and 125000 die due to complications
from the disease. Incidence is highest in the United States and
Northern Europe and lowest in Asia and Africa. The majority
of women are initially diagnosed after the primary tumour has
already metastasized, resulting in a 5-year survival of <30%.
The normal ovarian surface epithelium is mesenchymally derived
and tissue cohesion is provided by the mesenchymal N-cadherin
(neural cadherin). In contrast with most carcinomas that lose
epithelial characteristics with tumour progression, EOCs undergo
amesenchymal–epithelialtransition,acquireamoredifferentiated
phenotype and gain expression of E-cadherin (reviewed in [11]).
Figure 2 Ovarian tumours and the metastatic niche
Examples of epithelial ovarian carcinoma histotypes after haematoxylin and eosin staining at
×200 magniﬁcation: serous (A), endometrioid (B), mucinous (C) and clear cell (D). (E) Model
of ovarian cancer metastastatic niche. The model depicts a primary ovarian tumour arising from
malignanttransformationofovariansurfaceepithelium.SinglecellsandMCAsareshedfromthe
primary tumour into the peritoneal cavity. Accumulation of carcinomatous ascites is commonly
observed, particularly in women with advanced disease. Metastasis is the result of multiple
intraperitoneal adhesive events, whereupon tumour cells attach to peritoneal mesothelium,
disrupt mesothelial cell–cell contacts and migrate into the submesothelial matrix to anchor
secondary lesions on the bowel, diaphragm, omentum and other sites.
Duringprogression,tumoursacquiredifferentiatedcharacteristics
reminiscent of specialized Mullerian duct epithelia, resulting
in various histotypes of EOC. Thus serous EOC resemble
fallopian tubes, endometrioid EOC have characteristics of the
endometrium, mucinous EOC is similar to the endocervix and
clear-cellEOCtumoursresemblevaginaltissue(Figures2A–2D).
Clinically, tumours often involve the ovary and omentum,
with diffuse multi-focal intraperitoneal metastasis and malignant
ascites [12]. Malignant cells are exfoliated as single cells and
MCAs (multi-cellular aggregates) from the primary tumour
into the peritoneal cavity (Figure 2E), wherein distribution
is facilitated by peritoneal ﬂuid. Formation of malignant
ascites is believed to result from shed tumour-cell blockage
of peritoneal lymphatics and may further facilitate metastatic
dissemination. Shed tumour cells interact with mesothelial cells
lining the peritoneal cavity, induce mesothelial cell retraction and
anchor in the collagen-rich submesothelial matrix to establish
secondary lesions [13]. Adhesion of EOC cells to collagen
types I and III in the submesothelial matrix is mediated by
α2β1a n dα3β1 integrins [14–16]. This afﬁnity for interstitial
collagens is reﬂective of the mesenchymal origin of the ovarian
surface epithelium. β1 Integrin-mediated adhesion represents
an important early event in EOC metastatic dissemination, and
adhesion-mediated integrin signalling probably contributes to
metastatic success.
As EOC dissemination occurs largely within the peritoneal
cavity, a unique microenvironmental niche is established
comprised of tumour cells, inﬂammatory cells and soluble factors
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secreted by both the tumour and host cells including bioactive
lipids, growth factors, ECM (extracellular matrix) proteins and
inﬂammatory mediators. The contribution of the unique ovarian
carcinomamicroenvironmenttothedevelopmentandprogression
of metastatic disease is an area of active investigation. Aberrant
activation of numerous signalling pathways has been observed in
humanEOCthatresultinstimulatedproliferationordysregulated
cell death and most have been reviewed elsewhere. For example,
activation of receptor tyrosine kinases such as the EGFR [EGF
(epidermal growth factor) receptor] family and the VEGFR
(vascular EGFR) family is frequently observed in EOC and
regulates cell proliferation, survival, motility and metastasis
[17,18]. Moreover, activation of VEGFR also alters vascular
permeability, thereby contributing to build-up of ascites in EOC
patients [19].
Activation of PI3K (phosphoinositide 3-kinase) signalling is
observed in the majority of ovarian cancers as a result of
geneampliﬁcation,activatingmutationsoractivationdownstream
of receptor tyrosine kinases [20]. Signalling through the IL
(interleukin)-6 receptor is also observed in EOC and results
in nuclear translocation of STAT3 (signal transducer and
activator of transcription 3) and corresponding stimulation of
proliferationandangiogenesis[21].Cytokine-mediatedactivation
of NF-κB (nuclear factor κB) is also commonly detected in
ovarian tumours, leading to up-regulation of anti-apoptotic and
antioxidant gene products [22]. Lipid signalling via interaction of
LPA (lysophosphatidic acid) with LPA GPCRs is a potent means
of microenvironmental regulation, as LPA can be produced by
tumourcellsaswellasstromalcomponents,includingmesothelial
andinﬂammatorycells[23].LPAbindstosurfaceGPCRs,leading
toactivationofdiversesignallingpathwaysdependingontheLPA
receptorcomplementandthespeciﬁcG-proteinsexpressedbythe
cell. For example, LPA stimulation of Gα12/13 leads to activation of
thesmallGTPaseRhoA,resultingincytoskeletalchangesandcell
rounding [24]. In addition, secondary effects of LPA occur as a
result of induction of VEGF (vascular endothelial growth factor),
TGF (transforming growth factor) α,T G F β, IL-8, IL-6 and NF-
κB expression, thereby contributing to activation of additional
signalling pathways [25,26].
WNT SIGNALLING IN EOC
Progression of most cancers has been associated with activation
ofWntsignallingacquiredthroughtwomajorroutes:mutationsin
key components of the pathway or through mutation-independent
aberrant gene expression. For example, the majority of colon,
uterine and bladder tumours are strongly associated with APC,
Axinorβ-cateninmutations[27–31].Interestingly,manycancers,
including breast, prostate, lung, thyroid and pancreatic cancers
(reviewed in [32–37]), do not depend on mutations in APC, Axin
or β-catenin for activation of Wnt signalling.
Examples of Wnt signalling activation independent of mutations
in key Wnt signalling genes
The presence of nuclear or cytoplasmic β-catenin in human
breast cancer specimens is considered to be a strong indicator
of activated Wnt signalling in this malignancy [38]. Multiple
pathways, such as phosphorylation of β-catenin by EGFR/HER2
(human EGFR) [39], regulation of GSK3β activity by insulin,
IGF-1 (insulin-like growth factor-1) [40], ILK (integrin-linked
kinase)[41]orPI3K/Akt[42]andlossofPTEN(phosphataseand
tensinhomologuedeletedonchromosome10)[43]orp53[44,45],
have been associated with Wnt activation in breast cancers.
Interestingly, activation of Wnt signalling in prostate cancer
also depends on PTEN, PI3K/Akt [42] and IGF-1 [46], and can
additionally be regulated by the androgen receptor [47]. In lung
carcinoma, activation of Wnt signalling probably occurs through
routes involving overexpression of Dvl [48] and repression of
Wnt antagonists, such as WIF-1 and Dkk [49,50]. Activation
of Wnt signalling in pancreatic adenocarcinoma has been
related to overexpression of Wnt-1 and Fzd-2, which promotes
stabilization of β-catenin [37].
Histotype-dependent Wnt signalling activation in ovarian
carcinoma
MechanismsforactivationofWntsignallinginovariancarcinoma
exhibit histotype dependence. Thus only endometrioid EOC is
stronglyassociatedwithactivatingmutationsinβ-cateninleading
to constitutively active Wnt signalling. The majority of low-
grade endometrioid ovarian carcinomas often display nuclear
immunoreactivity for β-catenin (70% of cases), and these cases
often harbour mutations in the β-catenin gene at codons that
encode for residues phosphorylated by GSK3β (54% of cases)
[51]. Several studies conﬁrmed the predominance of nuclear
β-catenin and frequent β-catenin gene mutations in endometrioid
EOC as well as in cell lines derived from this histotype [52–54].
Nuclearβ-catenininlow-gradeendometrioidEOCalsoassociates
with squamous differentiation and correlates with good prognosis
and lack of relapse [51,55–57]. Moreover, expression of Wnt
target genes including FGF9 (ﬁbroblast growth factor 9) has been
described, suggesting that this pathway is active in endometrioid
carcinomas [55–57]. Mutations in Axin in cell lines of endomet-
rioid EOC have also been reported [54]; however, a distinct study
foundnomutationsineitherAPCorAxininhumanendometrioid
EOC [58]. Furthermore, high-grade endometrioid ovarian
carcinomas do not display nuclear β-catenin immunoreactivity
and progression is not associated with β-catenin mutations [51].
This evidence supports the existence of two distinct subtypes
of endometrioid EOC that may originate from different sources,
(reviewedin[59])basedondifferencesinmolecularpathobiology.
In contrast with endometrioid EOC, ovarian carcinomas of
serous, clear-cell and mucinous histotypes have only rarely been
associated with activating mutations in the key proteins of the
Wnt signalling pathway. One report identiﬁed cases of clear-cell
EOC positive for nuclear β-catenin [60]. Another study identiﬁed
mucinous EOC positive for mutations in the β-catenin gene
in the GSK3β-binding region [61]. Nevertheless, several lines
of evidence implicate activation of Wnt/β-catenin signalling in
serous EOC in the absence of activating mutations in either APC,
Axin or β-catenin. The strongest evidence is the presence of
nuclear β-catenin (Figure 1B). A broad range (3–59%) of serous
EOCs have been reported to contain nuclear and cytoplasmic
β-catenin [60,62,63]. It is noteworthy that a signiﬁcantly higher
percentage of high-grade (23%) serous EOC correlated with the
presence of nuclear β-catenin compared with low grade (2.1%)
[63], opposite from trends observed for endometrioid EOC [51].
Together,theseobservationssuggestthatadditionalfactorsinitiate
Wnt signalling activation in serous EOC progression.
Potential mechanisms of β-catenin stabilization in serous EOC
Nuclear factors
As described above, the results of several studies indicate that
ovarian carcinoma cells contain nuclear β-catenin, although
the percentage of positive tissues and positive cells within
each tested case vary widely. In the transcriptional activation
complex,β-cateninpartnerswithTcf/Lef,LeglessandPygopusto
initiate transcription. The presence of cytoplasmic Lef-1 has been
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Table 1 RNA expression of IDAX, BCL9 and RPL19 in EOC and normal ovary human specimens
Real-time reverse transcription–PCR was used to detect the levels of IDAX and BCL9 mRNAs in samples from non-cancerous ovarian tissues and ovarian carcinomas (Origene), according to
the manufacturer’s suggestions. Expression of RPL19 was detected as a positive control. Real-time PCR was carried out with the ABI Prizm (Applied Biosystems) and the Ct (threshold cycle)
values were obtained according to the manufacturer’s instructions. SYBR Green was used for quantitative PCR as a double-stranded DNA-speciﬁc ﬂuorophore. The following primers were used for
detectionofIDAX,BCL9 andRPL19 mRNAs:IDAX,forward5 -CAGCCAAGAAGAAGAGGA-3  andreverse5 -GGGAACAGGTGTTCTCTCTA3- ;BCL9,forward5 -ACGACCTCAGAGCAGAGTAT-3  and
reverse 5 -GACAAGACAGTGCTGAAGAG-3 ; RPL19, forward 5 -CAATGAAATCGCCAATGCCAACTC-3  and reverse 5 -TGGACCGTCACAGGCTTGC-3 . *Information obtained from the manufacturer
(OriGene) regarding Ovarian Carcinoma Panel I; †information on stage is related to ovarian carcinoma specimens only; ‡positive expression is deﬁned by Ct value below 35, whereas negative
expression (neg) is deﬁned as the absence of a detectible signal or Ct value equal or higher than 35. FIGO, International Federation of Gynecology and Obstetrics; AJCC, American Joint Committee
on Cancer.
Ct values‡
Diagnosis* Tumour grade* Stage† BCL9 IDAX RPL19
Adenocarcinoma of endometrium, papillary serous FIGO G3: poorly differentiated Non-cancerous 27.7 29.3 20
Carcinoma of cervix, squamous cell FIGO G3: poorly differentiated Non-cancerous 28.7 27.4 20
Abscess of tissue Not reported Non-cancerous 30.7 30.4 20
Endometriosis Not reported Non-cancerous 33.1 30.9 20
Endometriosis Not reported Non-cancerous 29.8 28.9 20
Endometriosis Not reported Non-cancerous 33.2 32.5 20
Endometriosis Not reported Non-cancerous 32.1 31.4 20
Carcinoma of ovary, endometrioid FIGO G2: moderately differentiated I 34.4 33.4 20
Adenocarcinoma of ovary, papillary serous FIGO G2: moderately differentiated IA 30.4 33.0 20
Tumour of ovary, papillary serous, borderline AJCC GB: borderline malignancy IA 31.7 33.0 20
Tumour of ovary, papillary serous, borderline AJCC GB: borderline malignancy IA 33.2 30.6 20
Carcinoma of ovary, endometrioid FIGO G1: well differentiated IA 28.9 neg 20
Tumour of ovary, serous, borderline AJCC GB: borderline malignancy IA 30.3 30.3 20
Tumour of ovary, borderline AJCC GB: borderline malignancy IA 32.2 33.0 20
Tumour of ovary, mucinous, borderline AJCC GB: borderline malignancy IA 33.3 31.0 20
Adenocarcinoma of ovary, mucinous FIGO G3: poorly differentiated IB 30.7 34.0 20
Adenocarcinoma of ovary, endometrioid FIGO G3: poorly differentiated IB 33.6 neg 20
Tumour of ovary, borderline Not reported IB 31.8 31.4 20
Tumour of ovary, mucinous, borderline AJCC GB: borderline malignancy IC 30.7 28.4 20
Tumour of ovary, serous, borderline AJCC GB: borderline malignancy IC 31.0 neg 20
Tumour of ovary, serous, borderline AJCC GB: borderline malignancy IC 32.2 33.0 20
Adenocarcinoma of ovary, mucinous FIGO G2: moderately differentiated IC 32.1 34.9 20
Adenocarcinoma of ovary, endometrioid, sq. feat. FIGO G2: moderately differentiated IC 30.0 31.9 20
Adenocarcinoma of ovary, serous FIGO G3: poorly differentiated IIB 31.4 31.7 20
Adenocarcinoma of ovary, endometrioid FIGO G3: poorly differentiated IIB 30.9 neg 20
Adenocarcinoma of ovary, endometrioid FIGO G1: well differentiated IIC 31.4 31.3 20
Adenocarcinoma of ovary, papillary serous FIGO G2: moderately differentiated III 29.2 32.0 20
Adenocarcinoma of ovary, serous FIGO G3: poorly differentiated III 28.7 neg 20
Carcinoma of ovary, endometrioid FIGO G2: moderately differentiated IIIA 33.9 30.3 20
Tumour of ovary, serous, borderline AJCC GB: borderline malignancy IIIA 31.6 31.7 20
Adenocarcinoma of ovary, papillary serous FIGO G3: poorly differentiated IIIB 30.5 neg 20
Adenocarcinoma of ovary, serous FIGO G2: moderately differentiated IIIB 30.5 neg 20
Adenocarcinoma of ovary, endometrioid FIGO G3: poorly differentiated IIIB 31.7 neg 20
Adenocarcinoma of ovary, papillary serous FIGO G2: moderately differentiated IIIB 31.5 neg 20
Adenocarcinoma of ovary, papillary serous FIGO G3: poorly differentiated IIIB 30.9 neg 20
Tumour of ovary, serous, borderline Not reported IIIB 31.0 33.3 20
Adenocarcinoma of ovary, metastatic Not reported IIIB 32.0 34.2 20
Adenocarcinoma of ovary, papillary serous FIGO G1: well differentiated IIIC 29.1 neg 20
Adenocarcinoma of ovary, papillary serous FIGO G3: poorly differentiated IIIC 33.2 31.3 20
Adenocarcinoma of ovary, papillary serous FIGO G3: poorly differentiated IIIC 32.7 31.1 20
Adenocarcinoma of ovary, papillary serous FIGO G3: poorly differentiated IIIC 32.5 32.2 20
Adenocarcinoma of ovary, papillary serous FIGO G3: poorly differentiated IIIC 31.0 34.6 20
Carcinoma of ovary FIGO G3: poorly differentiated IIIC 31.9 33.6 20
Adenocarcinoma of ovary, papillary serous Not reported IIIC 32.3 32.0 20
Adenocarcinoma of ovary, serous Not reported IIIC 32.4 neg 20
Adenocarcinoma of ovary, papillary serous FIGO G2: moderately differentiated IV 30.6 27.7 20
Adenocarcinoma of ovary, metastatic Not reported IV 32.0 30.9 20
Adenocarcinoma of ovary, papillary serous FIGO G3: poorly differentiated IV 32.6 neg 20
reportedinserousEOCandinNIH:OVCAR-3(aserousEOCcell
line).Theseauthorsalsodemonstratedco-immunoprecipitationof
Lef-1 and β-catenin in poorly differentiated stage III serous EOC
and NIH:OVCAR-3, but not in the normal ovary [9]. Comparison
of Lef-1 expression in ten specimens of normal ovary and 23
specimens of serous EOC revealed no differences between the
two groups [9]. The transcriptional co-activator Pygopus2 was
foundtobewidelyexpressedinovariancarcinomatissuesandcell
lines of all histotypes, and was demonstrated to be required for
tumour cell growth [64]. Furthermore, an additional co-activator
designated Legless (BCL9) is widely expressed in both human
EOCandnormalovaryspecimensattheRNAlevel(Table1).Thus
there are no apparent barriers for formation of the transcriptional
activation complex, as the key players are expressed in serous
EOC. Nevertheless, Wnt signalling is not constitutively activated
inthemajorityofserousEOCcasesorinthemajorityofindividual
cells in positive cases. However, it is important to note that
currentlyavailableapproachesdonotenabledetectionoftransient
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Figure 3 Wnt-5a in malignant EOC ascites
Malignant ascites were collected from women with EOC and non-malignant ascites were collected from women with ovarian hyperstimulation syndrome under an institutional review board-approved
protocolatNorthwesternUniversitySchoolofMedicine.Theproteinconcentrationofeachspecimenwasdeterminedandsamplescontainingequalprotein(1mg)wereelectrophoresedbySDS/PAGE,
electroblotted on to Immobilon membranes and analysed by Western blotting using anti-Wnt-5a primary antibody (1:1000 dilution; R&D systems) and peroxidase-conjugated goat anti-(rat IgG)
(1:5000 dilution; Santa Cruz Biotechnology). The blots were developed using enhanced chemiluminescence. Molecular mass in kDa is given on the left-hand side.
activation of Wnt signalling, suggesting that evaluation of Wnt
targetgeneexpressionmayprovidepotentialevidencewithwhich
to evaluate signalling pathway activation.
Cytoplasmic factors
There are several proteins that participate in the process of
phosphorylation and degradation of β-catenin in the cytoplasm,
thus preventing translocation into the nucleus. Expression of
GSK3β in 23 cases of primary and metastatic serous EOC
was approximately 6-fold higher on average than that in ten
normal ovarian tissues. Overexpression of FRAT1 (frequently
rearranged in advanced T-cell lymphomas 1), which inhibits
phosphorylationofβ-cateninbyGSK3β,stronglycorrelatedwith
nuclearβ-cateninanditsaccumulationinthecytoplasminhuman
serous EOC, suggesting a potential alternative mechanism for
β-catenin stabilization [60]. Cytoplasmic immunoreactivity for
APC was documented in 67 out of 113 (59%) serous EOC
and was comparable in primary and metastatic tumours [62],
suggestingthatcomponentsoftheβ-catenindegradationcomplex
are in place. The same study also reported that the absence of
cytoplasmic APC only rarely coincided with nuclear β-catenin
[62], suggesting that β-catenin degradation did not depend on the
presence of APC. Although no data are available regarding the
presence of Axin or Dvl, our ﬁndings suggest the presence of
a Dvl inhibitor, IDAX (inhibitor of the Dvl and Axin complex),
in both normal ovary and serous EOC tissues (Table 1). On the
basis of the currently available data it is tempting to speculate that
the equilibrium between cytoplasmic GSK3β and FRAT1 levels
could functionally regulate Wnt signalling activation in serous
EOC. In addition, a possible inhibition of Dvl through IDAX
could contribute to the liberation of GSK3β and Axin from the
complex with Frizzled, thus allowing for β-catenin degradation.
Membranous factors
ExpressionofFzd1andFzd5wastestedin26normalovaryand38
EOC(including22serous)specimens[65].Interestingly,ahigher
number of malignant specimens was positive for both receptors
relative to normal ovary (97.1% and 14.3% of malignant
EOC were FZD1- and FZD5-positive, whereas only 54.5% and
8.7% of the normal ovarian tissues were positive respectively).
Moreover, patients with FZD5-positive tumours had a 6-year
probability of survival of 0.2 compared with 0.55 for those with
FZD5-negative tumours. In addition, our data suggest that both
LRP-6 and Kremen are expressed at the RNA level in the serous
ovarian carcinoma cell line DOV13 (M.V. Barbolina and M.S
Stack, unpublished work). Furthermore, engagement of collagen-
binding β1 integrins, a process that occurs during adhesion
to submesothelial interstitial collagens in intraperitoneal EOC
metastasis, up-regulates LRP6 mRNA levels in serous OVCA
433 cells [66].
Secreted factors
Expression of an activator of canonical Wnt signalling, Wnt-1,
was found in a larger number of malignant EOC (29.4% out
of a total 38, of which 22 were serous) compared with normal
ovary (9.1% out of 26 total) specimens [65]. However, the same
study reported that the increase in Wnt-1 expression in malignant
EOC did not lead to stabilization of β-catenin [65]. Expression of
Wnt-5a was also highly positive in malignant EOC specimens
(80%) compared with those of the normal ovary (27.3%).
Of note, both Wnt-1- and Wnt-5a-positive EOC patients had a
signiﬁcantly lower chance of survival compared with their Wnt-
1-and Wnt-5a-negative counterparts [65]. Similar to the results
summarized above for LRP-6, collagen adhesion by serous EOC
cells also induces expression of Wnt-5a [66]. Furthermore, Wnt-
5a is prevalent in ascites ﬂuid obtained from women with EOC
(Figure 3). Although Wnt-5a is most commonly characterized
as an inhibitor of canonical Wnt signalling [67–72], emerging
evidence suggests that the pathway (canonical, non-canonical or
planar cell polarity) activated downstream of Wnt ligand-binding
is receptor context-dependent. Using in vitro models, Wnt-5a has
been shown to inhibit canonical Wnt signalling via an alternate
Wnt receptor, mRor2 (mammalian receptor tyrosine kinase-like
orphan receptor 2); however, Wnt-5a activates canonical Wnt
signalling in the presence of Fzd4 and LRP-5. This activation
potentiates nuclear β-catenin accumulation and activates Wnt
reporter constructs [73]. This is consistent with data showing
that Wnt-5a enhances the proliferation, migration and invasion of
pancreatic cancer cell lines via β-catenin-dependent signalling
pathways. In that study, Wnt5a treatment promoted nuclear
β-catenin localization, which was inhibited by siRNA (small
interfering RNA) targeted against Wnt-5a [74,75]. Additional
studies are needed to clarify the Wnt receptor/co-receptor proﬁles
of EOC cells of various histotypes to clarify the role of Wnt-5a in
EOC pathobiology.
Expression of Wnt target genes in EOC
Indirect evidence for the existence of active Wnt signalling
in serous EOC is expression of Wnt/β-catenin target genes in
c   The Authors Journal compilation c   2011 Biochemical Society © 2011 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.6 M. V. Barbolina, R. J. Burkhalter and M. S. Stack
Table 2 Expression of Wnt target genes in EOC
Overview of published data on Wnt target gene expression in EOC. BIRC5, survivin; CLDN,
claudin 1; EDN1, endothelin 1; FST, follistatin; MMP11, stromelysin 3; PLAUR, plasminogen
activator, urokinase receptor; PTTG, pituitary tumour-transforming 1; RARG, retinoic acid
receptor γ; SOX, sex-determining region box; JAG, jagged; SNAI,S n a i L .
Gene Reference(s)
CCND1 [78,79,167,168]
COX2 [111,169]
MMP2 [82,83]
MMP9 [83,170]
VEGF [171]
CD44 [172]
MET [173]
c-Myc [174]
PLAUR [175,176]
MMP7 [177]
CLDN [178]
BIRC5 [179]
EON1 [122,123]
JAG [180]
SOX9 [181]
SOX2 [182]
PTTG [183]
MMP26 [184]
SNAI [185]
FST [186]
RARG [187]
MMP11 [188]
LEF1 [189]
tumour cells or tissues. Currently over 100 target genes have
been identiﬁed, the transcription of which is regulated
by Wnt signalling (http://www.stanford.edu/∼rnusse/pathways/
targets.html). It should be noted, however, that many of these
genes are also known to be regulated by other pathways, such that
targetgeneexpressionaloneisnotsufﬁcientevidenceofactivated
Wnt signalling in serous EOC. Nevertheless, expression of
many Wnt target genes, including CCND1 (cyclin D1) [76–
79], COX2 (cyclo-oxygenase 2) [66,80], various MMPs (matrix
metalloproteinases) [13,14,81–85] and MET [86–87] is observed
in EOC, as summarized in Table 2, providing additional evidence
in support of Wnt pathway activation.
MICROENVIRONMENTAL ACTIVATION OF THE WNT PATHWAY
Intraperitoneal dissemination provides an unique microenviron-
ment for ovarian carcinoma metastases. As outlined in Figure 2,
progression of EOC is hallmarked by shedding of single and
multi-cellular aggregates of malignant epithelial cells from the
primary tumour [11,13]. Accumulation of malignant ascites in
the peritoneal cavity is common, particularly in women with
late-stage EOC. Thus metastasizing EOC cells exist in a milieu
rich in inﬂammatory cells [88] and growth/signalling factors,
including VEGF [89–91], EGF [11,92], TGFα,T G F β [93,94]
and LPA [23,95], providing ample opportunity for cross-talk
between signalling networks. Ascites accumulation also modiﬁes
peritoneal mechanobiology, altering the force environment
of both metastatic tumour cells and peritoneal mesothelium
[96,97]. Formation of secondary tumours at peritoneal organs
(colon, omentum, uterus and liver) is achieved by β1 integrin-
mediated anchoring to the mesothelium and submesothelial
matrix [14–16,98], representing a signiﬁcant transition from a
free-ﬂoating cell or aggregate to a three-dimensional matrix-
anchored structure. Within this unique metastatic niche, current
evidence suggests multiple opportunities for regulation of Wnt
signalling via molecular, mechanical and adhesion-dependent
microenvironmental cues.
LPA and LPA GPCRs
LPA, a bioactive lipid signalling molecule, plays a role in
numerous cell processes, including proliferation, migration,
adhesion and cell survival [23–26,99,100], by acting at a family
of GPCRs known as LPARs (LPA receptors) [101,102]. LPA has
wide-ranging inﬂuence on cell physiology and pathophysiology,
including increases in cytokine and growth factor expression,
alteration of surface-protein trafﬁcking and modulation of
transcription [103,104]. LPA, which is produced by both normal
andmalignantcells,ispresentinhighconcentration(2–80 μM)in
ascitesandserumfrom98%ofovariancancerpatients,including
those with early-stage disease [23,26,104–108]. Furthermore,
increasing LPA expression is correlated with poor prognosis,
suggesting its potential role as a therapeutic biomarker [109].
Results from our laboratory and others demonstrate LPA
regulation of proteases [MMP2, MMP9, MT1-MMP (membrane
type 1 MMP) and uPA (urokinase-type plasminogen activator)],
inﬂammatory signalling molecules (COX2), IL-8 and adhesion
moleculesincludingE-cadherinandβ1integrin[24,100,104,110–
111].Notably,E-cadherin-basedadherensjunctionsarestabilized
by β-catenin [112], and loss of junctional stability may increase
the cytoplasmic and/or nuclear pool of β-catenin [66].
LPA induces diverse cellular functions by activating one
of ﬁve known receptors (LPA1–5), which modulate various
signalling pathway proteins, including Rho/ROCK (Rho-
associated kinase), IP3 (inositol 1,4,5-triphosphate)/Ca
2+,P K C
(protein kinase C), PI3K, Ras/MAPK (mitogen-activated protein
kinase) and cAMP [101–117]. LPA1 (Gα12/13), LPA3 (Gαq/11)
and LPA4 (Gα12/13) receptor subtypes are expressed in the
ovary, with LPA4 being the most abundant. LPA2 and LPA3
are aberrantly overexpressed in several ovarian carcinoma cell
lines [103,104]. This observation has been conﬁrmed in vivo
by detection of overexpressed LPAR2 and LPAR3m R N Ai n
human ovarian tumour tissues, compared with normal and
benign tissues [105–107]. Furthermore overexpression of LPA2
and/or LPA3 potentiates a more proliferative and invasive
phenotype in ovarian tumour cells by modulating IL-6, IL-8
and VEGF expression [113]. Interestingly, heterotrimeric G-
proteinscontainingGα12/13 interactwiththecytoplasmicdomainof
E-cadherin, rescuing breast carcinoma cells from E-cadherin-
mediated migration suppression, preventing E-cadherin-based
cell aggregation and displacing β-catenin from the adherens
junction complex [114,115]. In colon cancer cell lines, LPA
treatment (1 μM) leads to robust inactivation of GSK3β and
nuclear localization of β-catenin [116]. These results correlate
with a previous study demonstrating that LPA treatment
(0.1–20 μM) or LPA2/LPA3 expression induced a deactivating
phosphorylation of GSK3β in HEK (human embryonic kidney)-
293 cells [117]. Recently, it has been shown that the
Gβγ subunit of the G-protein heterotrimer can also mediate
Wnt signalling, inhibiting β-catenin degradation and allowing
β-catenin-mediated transcriptional activity [118]. In support of
these ﬁndings, our unpublished work demonstrates that the LPA–
LPAR interaction disrupts junctional localization of E-cadherin
and induces nuclear translocation of β-catenin, suggesting a
mechanism for Wnt ligand-independent activation of Wnt/β-
catenin signalling in EOC (R. J. Burkhalter, Y. Liu and M.S.
Stack, unpublished work).
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Endothelins
The endothelins (ET-1, ET-2 and ET-3) are a family of peptide
signalling molecules that play a diverse role in physiology
and pathology. Biological function is achieved via autocrine
and paracrine signalling through two GPCRs, ETARa n dE T BR
(ET type A and B receptors respectively) [119,120]. ET-1 and
ETAR are overexpressed in ovarian cancer, driving epithelial-to-
mesenchymal transition by stimulating tumour cell proliferation,
invasive propensity (migration and adhesion), tumour cell escape
from apoptosis and angiogenesis through multiple signalling
pathways [120–123]. The ET-1/ETAR axis has been shown to
promote the invasive phenotype via inhibition of GSK3β in
an ovarian carcinoma cell line [123]. Studies have shown a
ETAR/β-arrestin-1/Src signalling complex activates ILK, leading
to GSK3β inhibition [124,125]. Subsequently, this activity leads
to down-regulation of E-cadherin and increased Snail and β-
catenin levels, promoting epithelial-to-mesenchymal transition
[126,127]. Interestingly, studies in colon cancer and prostate can-
cer suggest reciprocal β-catenin regulation of ET-1 transcription
through interaction with Tcf-4 [128,129]. These results suggest a
potential signalling feed-forward loop for co-ordinate regulation
ofβ-cateninandET-1tosustainanaggressiveinvasivephenotype
necessary for tumour progression to metastasis.
Integrin-mediated matrix engagement activates β-catenin
signalling
During the ovarian carcinoma metastatic cascade, disseminating
cells anchor to the mesothelium and submesothelial matrix
of peritoneal organs [11,13]. Although mechanisms regulating
mesothelial receptivity have not been fully investigated,
mechanical deformation of the mesothelium caused by
accumulated ascites ﬂuid may expose submesothelial matrix
and/or modulate surface-expressed proteins on mesothelial cells
themselves [130]. Additionally, a ﬁbronectin-rich adhesion-
promoting stroma is deposited on the otherwise non-
adhesive mesothelium [131,132] Several studies have recently
demonstrated a link between integrin signalling and the Wnt/β-
catenin pathway activation in physiological and pathological cell
signalling processes [66,133–138]. Our laboratory has modelled
submesothelial anchoring of metastasizing EOC cells using
three-dimensionalcollagenmatricesormicrosphere-immobilized
anti-(β1 integrin) antibodies to mimic matrix-induced integrin
aggregation. Integrin clustering in the serous EOC cell lines
OVCA 429 and OVCA 433 results in rapid loss of junctional
E-cadherin, dissolution of adherens junctions and loss of surface-
localized β-catenin [66]. β-Catenin is translocated to the
nucleus wherein it activates transcription of Tcf/Lef target genes,
including LRP6 and Wnt5a [66]. Similarly, culturing the serous
EOC cell line DOV13 in three-dimensional collagen gels leads
to down-regulation of two secreted antagonists of Wnt signalling,
CTGF (connective tissue growth factor) [139] and DKK1 [16].
Interestingly, down-regulation of DKK1 and CTGF also occurs
in DOV13 cells cultured as spheroids relative to two-dimensional
tissue culture (Table 3). On the basis of these results, it is
interesting to speculate that activation of Wnt signalling in free-
ﬂoating MCAs may contribute to the acquired chemoresistance
of this cell population.
The mechanical microenvironment may modulate Wnt signalling
through β-catenin
More than two-thirds of all cases of EOC simultaneously present
with malignant ascites. Ascites development in progressive
or recurrent disease is a poor prognostic indicator and is
Table3 ChangesinexpressionofgenesrelatedtoWntsignallinginovarian
carcinoma MCAs compared with monolayers
Cells were cultured as monolayers or MCAs. To create MCAs, cells were released from the
monolayersusingtrypsin/EDTAsolution,resuspendedinminimalessentialmediumcontaining
2% fetal bovine serum, plated over solidiﬁed 0.5% agarose, and allowed to form spheroids
overnight at 37◦C and 5% CO2. Total RNA for cDNA microarray experiments was extracted
using TRIzol® (Invitrogen), according to the manufacturer’s instructions. All DNA microarray
gene expression studies used human oligonucleotide arrays custom printed by a dedicated
core facility within the Eppley Institute for Research in Cancer and Allied Diseases, University
of Nebraska Medical Center (Omaha, N.E., U.S.A.) as described previously [16]. Microarray
slides were scanned with a ScanArray 4000 confocal laser system (PerkinElmer). Analysis
of microarray gene expression data, accumulated from three independent experiments, was
performed as described [16]. n/a, not applicable. VCAN, versican.
Gene Up-regulation (fold) Down-regulation (fold) Cell line
DKK1 n/a 3.3 DOV13, ES2
CTGF n/a 3.4 DOV13
VCAN 2.2 n/a DOV13
CCND1 2.3 n/a ES2
correlated with a lack of response to treatment [140–142]. In
comparison with the peritoneal cavity of disease-free women
that contains approximately 20 ml of peritoneal ﬂuid, ascitic
volumes average 4.9 litres in EOC patients, with a range of
0.8 to 15 litres [143–145]. Although biological components of
ascites are increasingly shown to inﬂuence progression of ovarian
cancer via diverse signalling pathways [74,146,147], potential
biomechanical signals activated by increasing intraperitoneal
ﬂuid pressure have not been investigated. Tumour cells sense
alterations in the force environment via mechanosensing cell-
surface-expressed proteins, including integrins, and subsequent
‘inside-out’integrinsignallinginducescytoskeletalmodiﬁcations
that effect cell behaviour [148–151]. Force modulation in the
contextofthree-dimensionalmatrixrigidityisunderinvestigation
in several other tumour types [140,149,152–154]; however, the
potential effects of the complex mix of strain, compression
and shear forces conferred by ascites ﬂuid are unknown. Our
preliminary results show that static strain results in loss of
surface-associated E-cadherin in serous EOC cells (J. Symowicz
and M.S. Stack, unpublished work). In colon cancer, laminar
shear stress increased DKK1 expression and decreased activated
β-catenin [155]. Conversely, transient compression in APC-
deﬁcient cell lines facilitated phosphorylation of β-catenin,
leading to destabilization of adherens junctions, nuclear
translocation of β-catenin and transcriptional activation of the
β-catenin target genes Myc and Twist1 [156]. These results
highlighttheneedtoconsidermultipledistinctmechanicalstimuli
when modelling the force microenvironment of tumour tissues.
FUTURE PERSPECTIVES
As summarized above and in Figure 4, the unique microenviron-
mental niche inhabited by ovarian tumours provides a number
of diverse mechanisms for transcriptional activation of Wnt/
β-catenin target gene expression, even in histotypes devoid of
activating mutations in Wnt pathway components. As canonical
Wnt signalling is known to regulate proliferation, differentiation
and ‘stemness’ [157], clearly additional studies are needed to
provide a more detailed understanding of the role of Wnt target
gene expression in ovarian tumour progression and metastasis.
In particular, the contribution of microenvironmentally regulated
Wnt/β-catenin signalling to maintenance of stemness properties
in the self-renewing population of ovarian-cancer-initiating cells
[158] remains to be explored. As many extracellular proteinases
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Figure 4 Potential mechanisms for activation of Wnt/β-catenin signalling in the ovarian tumour microenvironment
In the absence of activating mutations in key components of the Wnt signalling pathway, microenvironmental factors may contribute to transcriptional activation of Wnt/β-catenin target genes. For
example, interaction of LPA with LPAR or ET with ET receptors (ETR) have been shown to block the activity of GSK3β, thereby resulting in increased nuclear translocation of β-catenin and enhanced
β-catenin-mediated transcriptional activity (left-hand panel). Lateral aggregation of collagen-binding β1 integrins leads to dissolution of adherens junctions and enhanced nuclear translocation of
β-catenin. In addition, integrin aggregation enhances the expression of LRP-6 and Wnt-5a while down-regulating the Wnt pathway inhibitors DKK and CTGF. Mechanical compression, exerted on
MCAs of metastasizing EOC cells in the form of increased intraperitoneal ﬂuid pressure due to accumulated ascitic ﬂuid, may also destabilize adherens junctions and promote nuclear translocation
of β-catenin (right-hand panel).
are β-catenin target genes, analysis of the involvement of this
pathway in proteinase-mediated intraperitoneal anchoring of
metastatic EOC cells may also prove informative.
A number of compounds have been identiﬁed that target
various components of the Wnt signalling pathway [1,159–
161]. For example, non-steroidal anti-inﬂammatory drugs do not
block Wnt signalling themselves, but can induce degradation
of Tcf or inhibit Wnt targets such as COX2 [162]. Various
small-molecule inhibitors of β-catenin–Tcf interaction have been
identiﬁed that disrupt β-catenin–Tcf binding, decrease reporter
gene transcription, inhibit cell proliferation in vitro and block
tumour growth in murine models [163–165]. An alternative
approach has been to utilize compounds that stabilize Axin,
thereby stimulating β-catenin degradation [166]. As summarized
above, with the exception of endometrioid ovarian tumours,
progression of EOC has not been commonly associated with
activated Wnt signalling. Consequently, there is no available
literature reporting the efﬁcacy of Wnt signalling inhibitors
in serous EOC, and a search of the clinical trials database
(www.clinicaltrials.gov) for trials involving EOC patients and
Wntsignallinginhibitorsreturnednohits.Nevertheless,inlightof
the accumulating evidence in support of activated Wnt signalling
inEOCandincreasingevidenceforligand-independentactivation
of the pathway through microenvironment-regulated cross-talk,
preclinical studies evaluating the potential efﬁcacy of small-
molecule inhibitors of this signalling pathway are warranted.
Following successful preclinical trials, future human clinical
trials should be designed to identify the subset of patients most
likely to beneﬁt from this biologically targeted therapy (for
example,showingnuclearβ-cateninstaining)andtousevalidated
biomarkers of response.
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